---
title: "Hong Kong stock movement: GUIXIN GROUP fell 13.68%"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/261168716.md"
description: "GUIXIN GROUP fell 13.68%; Longpan Technology rose 0.86%, with a transaction volume of HKD 45.81 million; China Xuyang Group fell 1.27%, with a transaction volume of HKD 4.97 million; Shanghai Petrochemical Company had a transaction volume of HKD 4.56 million; Li Auto rose 1.05%, with a market value of HKD 3.96 billion"
datetime: "2025-10-15T03:02:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/261168716.md)
  - [en](https://longbridge.com/en/news/261168716.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/261168716.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/261168716.md) | [English](https://longbridge.com/en/news/261168716.md)


# Hong Kong stock movement: GUIXIN GROUP fell 13.68%

**Hong Kong Stock Movement**

**Stocks with High Trading Volume in the Industry**

Longpan Technology rose 0.86%. There has been no significant news recently; trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Shanghai Petrochemical Company, with a trading volume of HKD 4.56 million. There has been no significant news recently; trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

### 相關股票

- [GUIXIN GROUP (08349.HK)](https://longbridge.com/zh-HK/quote/08349.HK.md)

## 相關資訊與研究

- [China's detentions of Panama-flagged vessels raise concerns, Rubio says](https://longbridge.com/zh-HK/news/281541796.md)
- [Osl Group FY adjusted non-IFRS income HK$534.1 million](https://longbridge.com/zh-HK/news/281223382.md)
- [Shin Hwa World logs FY revenue HK$966.9 mln](https://longbridge.com/zh-HK/news/281055310.md)
- [Xinhua Pharma Becomes Marketing Authorization Holder of Dental Drug After Regulatory Nod](https://longbridge.com/zh-HK/news/281343251.md)
- [CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint](https://longbridge.com/zh-HK/news/281325910.md)